Results from the SOUL Trial: The Cardiologists' Perspective

Échec de l'ajout au panier.

Veuillez réessayer plus tard

Échec de l'ajout à la liste d'envies.

Veuillez réessayer plus tard

Échec de la suppression de la liste d’envies.

Veuillez réessayer plus tard

Échec du suivi du balado

Ne plus suivre le balado a échoué

Results from the SOUL Trial: The Cardiologists' Perspective

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

Last week we heard the diabetologist's perspective on cardiovascular outcomes. In this weeks episode, EASD TV continues its deep dive into major clinical trials with the cardiologist’s perspective. Cardiologist Dr. Matthew Cavender (University of North Carolina) joins Vivienne Parry to unpack the SOUL trial, a major cardiovascular outcomes study evaluating oral semaglutide in people with type 2 diabetes. The trial followed more than 8,000 high-risk participants and demonstrated a 14% reduction in major cardiovascular events, including cardiovascular death, myocardial infarction and stroke. Dr Cavender explains why having an effective oral GLP-1 receptor agonist is an important development for both diabetes and cardiovascular care, and what the findings mean for clinical practice, guideline implementation, and patient access. From cross-disciplinary teamwork to the future of evidence-based prescribing, this episode offers a clear look at how the SOUL trial is shaping modern treatment strategies.

Pas encore de commentaire